[go: up one dir, main page]

CL2022002849A1 - crystalline ret inhibitor - Google Patents

crystalline ret inhibitor

Info

Publication number
CL2022002849A1
CL2022002849A1 CL2022002849A CL2022002849A CL2022002849A1 CL 2022002849 A1 CL2022002849 A1 CL 2022002849A1 CL 2022002849 A CL2022002849 A CL 2022002849A CL 2022002849 A CL2022002849 A CL 2022002849A CL 2022002849 A1 CL2022002849 A1 CL 2022002849A1
Authority
CL
Chile
Prior art keywords
crystalline
ret inhibitor
ret
crystalline form
diseases
Prior art date
Application number
CL2022002849A
Other languages
Spanish (es)
Inventor
Miglani Bhardwaj Rajni
Steven KERR Mark
Patton Kjell Douglas
Miles Merritt Jeremy
Gordon Selbo Jon
Krishna Viswanath Shekhar
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of CL2022002849A1 publication Critical patent/CL2022002849A1/en
Priority to CL2024002944A priority Critical patent/CL2024002944A1/en
Priority to CL2024002943A priority patent/CL2024002943A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Semiconductor Lasers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En el presente documento se proporciona una forma cristalina de selpercatinib útil en el tratamiento y prevención de enfermedades que pueden tratarse con un inhibidor de la quinasa RET, incluidos enfermedades y trastornos asociados con RET, y métodos para preparar esta forma cristalina.Provided herein is a crystalline form of selpercatinib useful in the treatment and prevention of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders, and methods for preparing this crystalline form.

CL2022002849A 2020-04-17 2022-10-14 crystalline ret inhibitor CL2022002849A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CL2024002944A CL2024002944A1 (en) 2020-04-17 2024-09-30 Crystalline form of ret kinase inhibitor.
CL2024002943A CL2024002943A1 (en) 2020-04-17 2024-09-30 Crystalline form of ret kinase inhibitor.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063011701P 2020-04-17 2020-04-17
US202163151354P 2021-02-19 2021-02-19

Publications (1)

Publication Number Publication Date
CL2022002849A1 true CL2022002849A1 (en) 2023-06-16

Family

ID=75747118

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2022002849A CL2022002849A1 (en) 2020-04-17 2022-10-14 crystalline ret inhibitor
CL2024002943A CL2024002943A1 (en) 2020-04-17 2024-09-30 Crystalline form of ret kinase inhibitor.
CL2024002944A CL2024002944A1 (en) 2020-04-17 2024-09-30 Crystalline form of ret kinase inhibitor.

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2024002943A CL2024002943A1 (en) 2020-04-17 2024-09-30 Crystalline form of ret kinase inhibitor.
CL2024002944A CL2024002944A1 (en) 2020-04-17 2024-09-30 Crystalline form of ret kinase inhibitor.

Country Status (18)

Country Link
EP (1) EP4136090A1 (en)
JP (2) JP7608474B2 (en)
KR (1) KR20230002706A (en)
CN (1) CN115916791A (en)
AU (1) AU2021255488B2 (en)
BR (1) BR112022020446A2 (en)
CA (1) CA3174316A1 (en)
CL (3) CL2022002849A1 (en)
CO (1) CO2022014882A2 (en)
CR (1) CR20220520A (en)
DO (1) DOP2022000221A (en)
EC (1) ECSP22080982A (en)
IL (1) IL297212A (en)
MX (1) MX2022012952A (en)
PE (1) PE20230388A1 (en)
PH (1) PH12022552748A1 (en)
TW (1) TWI865765B (en)
WO (1) WO2021211380A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022069357A1 (en) * 2020-10-01 2022-04-07 Sandoz Ag Crystalline form of selpercatinib
US20230183266A1 (en) * 2021-12-13 2023-06-15 Loxo Oncology, Inc. Crystalline forms of ret inhibitor and preparation thereof
TW202504611A (en) 2023-03-30 2025-02-01 美商銳新醫藥公司 Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI704148B (en) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI876442B (en) * 2017-10-10 2025-03-11 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TWI783057B (en) * 2017-10-10 2022-11-11 美商絡速藥業公司 Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
WO2020064009A1 (en) * 2018-09-30 2020-04-02 北京志健金瑞生物医药科技有限公司 Substituted pyrazole fused ring derivative, preparation method therefor, and application thereof
CN111004257B (en) * 2019-12-24 2021-06-29 武汉九州钰民医药科技有限公司 Method for preparing RET inhibitor Selpercatinib

Also Published As

Publication number Publication date
CO2022014882A2 (en) 2022-10-31
JP7608474B2 (en) 2025-01-06
WO2021211380A1 (en) 2021-10-21
AU2021255488B2 (en) 2024-05-30
TW202202501A (en) 2022-01-16
DOP2022000221A (en) 2023-01-15
TWI865765B (en) 2024-12-11
IL297212A (en) 2022-12-01
KR20230002706A (en) 2023-01-05
MX2022012952A (en) 2023-01-11
JP2023522012A (en) 2023-05-26
CA3174316A1 (en) 2021-10-21
AU2021255488A1 (en) 2022-11-10
ECSP22080982A (en) 2023-01-31
JP2025020140A (en) 2025-02-12
CR20220520A (en) 2022-11-15
BR112022020446A2 (en) 2022-11-29
EP4136090A1 (en) 2023-02-22
PE20230388A1 (en) 2023-03-06
PH12022552748A1 (en) 2024-03-25
CL2024002943A1 (en) 2025-05-30
CL2024002944A1 (en) 2025-04-04
CN115916791A (en) 2023-04-04

Similar Documents

Publication Publication Date Title
CL2024002944A1 (en) Crystalline form of ret kinase inhibitor.
DOP2019000163A (en) COMPOUNDS OF 7-PHENYLETHYLAMINE-4H-PYRIMID [4,5-D] [1,3] -OXAZIN-2-ONA AS INHIBITORS OF IDH1 AND IDH2 MUTANTS
CO2019004650A2 (en) Pyrazolo [1,5-a] pyridine compounds substituted as ret kinase inhibitors
DOP2019000180A (en) INHIBITORS OF TGFß1 ISOFORM-SPECIFIC CONTEXT-PERMISIVES AND USE OF THE SAME
CO2021006075A2 (en) Compounds and compositions for the treatment of conditions associated with the activity of nlrp
CL2018002708A1 (en) Methods for inhibition of angiogenesis in a subject in need
CL2018000119A1 (en) Pyrazolo [1,5-a] pyridine compounds substituted as ret kinase inhibitors.
ECSP18094983A (en) PIRAZOLE DERIVATIVES AS INHIBITORS OF PLASMA CALICREIN
MX389468B (en) GLYCERYL 3-HYDROXYBUTYRATES FOR THE CONTROL OF MIGRAINE SYMPTOMS
ECSP19014247A (en) DOSAGE FORMS TO TREAT AND PREVENT SLEEP DISORDERS
CR20150450A (en) KINAZOLINIC INHIBITORS OF ACTIVATE MUTED FORMS OF THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR
ECSP11010824A (en) TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN.
CL2020000382A1 (en) Compositions of amino acids for the treatment of liver disease.
CO2024009571A2 (en) Parp1 inhibitors
AR048833A1 (en) PROCEDURE FOR THE TREATMENT OF PREMENSTRUAL DISORDERS AND OTHER FEMALE SEXUAL DISORDERS
CL2020002544A1 (en) Ret inhibitor for use in treating cancer that has a ret alteration
BR112022001393A2 (en) Crystalline form of atr inhibitor and its use
MX2017009246A (en) COMBINATION PHARMACO.
CL2024000776A1 (en) Milvexian for the prevention and treatment of thromboembolic disorders
CO2019007879A2 (en) Crystalline forms of tebipenem pivoxil, compositions including them, manufacturing methods, and methods of use
CO2021008535A2 (en) Quinoline compounds as tam and met kinase inhibitors
AR095594A1 (en) METHODS TO TREAT INFECTIONS IN PATIENTS WITH OVERWEIGHT AND OBESOS USING ANTIBIOTICS
CO2023017186A2 (en) Crystalline forms of trofinetide
AR061618A1 (en) TEMOZOLOMIDE UNIT DOSAGE FORMS
MX2024007017A (en) Processes for the preparation of the crystalline form a of selpercatinib. a ret inhibitor.